Peptide Basics

Tirzepatide, Survodutide, Mazdutide and Retatrutide are all studied in metabolic research, but they do not activate the same combination of receptors. Tirzepatide targets GLP-1 and GIP receptors. Survodutide and Mazdutide target GLP-1 and glucagon receptors. Retatrutide brings all three pathways—GLP-1, GIP and glucagon—into one research model. Mile High Peptides LLC is a U.S.-based supplier of…

What Is Mazdutide (IBI362)? GLP-1 & Glucagon Receptor Research Explained Mazdutide, also known as IBI362 and LY3305677, is a peptide studied for activity involving two important metabolic receptor systems: the GLP-1 receptor and the glucagon receptor. Because Mazdutide interacts with both receptor systems, it is classified as a dual GLP-1/glucagon receptor agonist. In simple terms,…

What Is Survodutide (BI 456906)? GLP-1 & Glucagon Receptor Research Explained Survodutide, also known by the research designation BI 456906, is a peptide studied for activity involving two important metabolic receptor systems: the GLP-1 receptor and the glucagon receptor. Because it interacts with both receptor systems, Survodutide is classified as a dual GLP-1/glucagon receptor agonist….

What Is ARA-290 (Cibinetide)? Research, EPOR/CD131 Signaling & Repair Pathways ARA-290, also known as Cibinetide, is a research peptide studied for its interaction with cellular signaling systems associated with tissue stress, inflammatory responses and repair-related biological processes. Unlike research compounds centered primarily on metabolic receptors, ARA-290 is commonly investigated in models designed to help researchers…

If you have researched peptide therapy, compounded medications, or telehealth wellness services, you may have encountered the terms 503A pharmacy and 503B outsourcing facility. These designations are frequently misunderstood. One of the biggest misconceptions is that a 503A or 503B designation gives a pharmacy permission to compound any peptide requested by a healthcare provider. It…